Etienne Meylan

Etienne Meylan

Auto-generated profile, based on publicly available information

Etienne Meylan

Laboratory of Immunobiology, Department of Molecular Biology, Faculty of Sciences, Université Libre de Bruxelles, Gosselies, Belgium

Research Focus & Metrics

Academic Career Length

25Years (2002-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
21 October 2009 in Nature
Verified
Journal Article
Open access
PDF file
DBDavid A. Barbie
David A. Barbie
PTPablo Tamayo
Pablo Tamayo
JBJesse S. Boehm
Jesse S. Boehm
SKSo Young Kim
So Young Kim
SMSusan E. Moody
Susan E. Moody
WHWilliam C. Hahn
William C. Hahn
Mutations in genes of the RAS family are preset on about 20% of human cancers, making RAS proteins prime potential targets for cancer therapy. Direct targeting of RAS proteins has not so far been productive, but two papers published in this issue offer the prospect of alternative targets in a signalling pathway downstream of RAS. Using a synthetic lethality RNAi screen, Barbie et al. identify TBK1 as a kinase in the NF-κB signalling pathway that is essential for the survival of KRAS-transformed cells. TBK1 induces anti-apoptotic signals and may be a therapeutic cancer target. And in an elegant mouse model for lung cancer driven by Kras mutation and loss of p53, Meylan et al. show that NF-κB signalling is activated by the concerted actions of these two alterations and required for tumour initiation and tumour maintenance. KRAS is a proto-oncogene that is mutated in a wide variety of human cancers. Although this makes KRAS an obvious candidate for the development of targeted therapies, it has so far remained refractory to this approach. Systematic RNA interference is now used to detect synthetic lethal partners of oncogenic KRAS, revealing that TBK1 and NF-κB signalling are essential in KRAS mutant tumours. This may provide an alternative approach for targeting KRAS therapeutically. The proto-oncogene KRAS is mutated in a wide array of human cancers, most of which are aggressive and respond poorly to standard therapies. Although the identification of specific oncogenes has led to the development of clinically effective, molecularly targeted therapies in some cases, KRAS has remained refractory to this approach. A complementary strategy for targeting KRAS is to identify gene products that, when inhibited, result in cell death only in the presence of an oncogenic allele1,2. Here we have used systematic RNA interference to detect synthetic lethal partners of oncogenic KRAS and found that the non-canonical IκB kinase TBK1 was selectively essential in cells that contain mutant KRAS. Suppression of TBK1 induced apoptosis specifically in human cancer cell lines that depend on oncogenic KRAS expression. In these cells, TBK1 activated NF-κB anti-apoptotic signals involving c-Rel and BCL-XL (also known as BCL2L1) that were essential for survival, providing mechanistic insights into this synthetic lethal interaction. These observations indicate that TBK1 and NF-κB signalling are essential in KRAS mutant tumours, and establish a general approach for the rational identification of co-dependent pathways in cancer.

21 September 2005 in Nature
Verified
Journal Article
Open access
PDF file
EMEtienne Meylan
Etienne Meylan
JCJoseph Curran
Joseph Curran
KHKay Hofmann
Kay Hofmann
DMDarius Moradpour
Darius Moradpour
Marco BinderMarco Binder
Marco Binder
JTJürg Tschopp
Jürg Tschopp
Antiviral immunity against a pathogen is mounted upon recognition by the host of virally associated structures. One of these viral ‘signatures’, double-stranded (ds) RNA, is a replication product of most viruses within infected cells and is sensed by Toll-like receptor 3 (TLR3) and the recently identified cytosolic RNA helicases RIG-I (retinoic acid inducible gene I, also known as Ddx58) and Mda5 (melanoma differentiation-associated gene 5, also known as Ifih1 or Helicard)1. Both helicases detect dsRNA, and through their protein-interacting CARD domains, relay an undefined signal resulting in the activation of the transcription factors interferon regulatory factor 3 (IRF3) and NF-κB. Here we describe Cardif, a new CARD-containing adaptor protein that interacts with RIG-I and recruits IKKα, IKKβ and IKKɛ kinases by means of its C-terminal region, leading to the activation of NF-κB and IRF3. Overexpression of Cardif results in interferon-β and NF-κB promoter activation, and knockdown of Cardif by short interfering RNA inhibits RIG-I-dependent antiviral responses. Cardif is targeted and inactivated by NS3-4A, a serine protease from hepatitis C virus known to block interferon-β production. Cardif thus functions as an adaptor, linking the cytoplasmic dsRNA receptor RIG-I to the initiation of antiviral programmes.

6 July 2006 in Nature
Verified
Journal Article
Closed access
PDF file
EMEtienne Meylan
Etienne Meylan
JTJürg Tschopp
Jürg Tschopp
MKMichael Karin
Michael Karin

4 April 2004 in Nature Immunology
Verified
Journal Article
Closed access
PDF file
EMEtienne Meylan
Etienne Meylan
KBKim Burns
Kim Burns
KHKay Hofmann
Kay Hofmann
VBVincent Blancheteau
Vincent Blancheteau
FMFabio Martinon
Fabio Martinon
JTJürg Tschopp
Jürg Tschopp

17 February 2020 in Nature Immunology
Verified
Journal Article
Closed access
PDF file
HWHaiping Wang
Haiping Wang
FFFabien Franco
Fabien Franco
YTYao-Chen Tsui
Yao-Chen Tsui
XXXin Xie
Xin Xie
MTMarcel P. Trefny
Marcel P. Trefny
PHPing-Chih Ho
Ping-Chih Ho

1 November 2004 in Current Biology
Verified
Journal Article
Closed access
FMFabio Martinon
Fabio Martinon
LALaetitia Agostini
Laetitia Agostini
EMEtienne Meylan
Etienne Meylan
JTJürg Tschopp
Jürg Tschopp